Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin Combined With Bevacizumab and FOLFIRI for Liver Metastases From Colorectal Cancer
NCT06269445Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2024
- Primary completion
- Feb 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Icaritin in colorectal cancer (CRC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Progression-free survival up to 5 years. Started Jan 2024; status: recruiting.
02
Drugs
Icaritin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06269445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06269445.